Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis

CONCLUSIONS: The TLPO and TLPLDC (without G-CSF) vaccines were associated with improved DFS and OS in this clinical trial. Given production and manufacturing advantages, the efficacy of the TLPO vaccine will be confirmed in a phase 3 trial.TRIAL REGISTRATION NUMBER: NCT02301611.PMID:37536936 | DOI:10.1136/jitc-2023-006665

Source: Cancer Control - August 3, 2023 Category: Cancer & Oncology Authors: Elizabeth Lee Carpenter Spencer Van Decar Alexandra M Adams Anne E O'Shea Patrick McCarthy Robert Connor Chick Guy Travis Clifton Timothy Vreeland Franklin A Valdera Ankur Tiwari Diane Hale Phillip Kemp Bohan Annelies Hickerson Todd Smolinsky Katryna Thom Source Type: research